Re: "Collision of Evidence and Assumptions: TMI Déjà View" by Talbott, EO et al.
Meta-Analyses of TCE
Carcinogenicity 
We read with interest the recent report by
Wartenberg et al. (1) in which they described
an “ad hoc system” and “meta-analysis–type
approach” for evaluating the carcinogenicity
of trichloroethylene (TCE). In particular, we
are concerned that their methods may
obscure rather than clarify the relationship
between TCE and human cancer.
Briefly, Wartenberg et al. (1) catego-
rized studies on the basis of their design:
cohort, case–control, community-based,
and case series. Cohort studies were then
divided “into three tiers based on the speci-
ficity of the exposure information” con-
tained in each. Next, the authors estimated
the average relative risk for each tier, which
was calculated using 
a weighted average of the individual measures of
effect, where the weights are the inverse of the
variance of the individual measures.
That approach, although defensible (2), does
not necessarily lead to results that are either
biologically or epidemiologically meaningful.
To the contrary, it may encourage analysis of
groups of studies that would more logically
be analyzed separately. Such meta-analyses
can either amplify or conceal underlying
causal associations.
This can be illustrated by reference to  the
analysis of kidney cancer incidence rates in the
cohort studies (1). There were seven Tier I
cohort studies, of which six are large occupa-
tional cohort studies: Anttila et al. (3), Axelson
et al. (4), Blair et al. (5), Boice et al. (6),
Morgan et al. (7), and Ritz (8). Four of the
Tier I studies included incidence data used to
calculate a summary relative risk for renal can-
cer incidence. Of these four, three were large
cohort studies [Anttila et al. (3), Axelson et al.
(4), and Blair et al. (5)] that considered renal
cancer in 18,182 individuals (12,848 exposed
to TCE). The fourth of these studies,
Henschler et al. (9), was a small study of only
359 subjects (169 exposed to TCE), which has
been the subject of ongoing methodologic
controversy and debate because it originated as
an investigation of a cancer cluster. For that
reason, the International Agency for Research
on Cancer (IARC) did not include it when
calculating summary relative risks in its assess-
ment of TCE and human cancer (10).
To determine the impact of including
the Henschler study (9), we recalculated
Wartenberg’s computations, using their
inverse variance-weighted technique, with
and without the Henschler data. The sum-
mary relative risk for renal cancer in the
three large cohorts excluding the Henschler
study was 0.98 [95% confidence interval
(CI), 0.58–1.66]. Including the Henschler
data (9), the summary relative risk is 1.7
(95% CI, 1.1–2.7), which agrees with the
calculations of Wartenberg et al. (1).
Although inclusion of the Henschler study
increased the combined study population by
only 169 exposed and 359 total subjects
(1.32% and 1.97%, respectively), it
increased the relative risk by nearly 74% and
reversed the conclusions of the analysis. 
The impact of the Henschler data (9)
stems from its very high incidence rate of
renal cancer, about 8-fold higher than that of
the other cohorts. It is therefore important
whether this population was studied because
of a renal cancer cluster in that small TCE-
exposed worksite, a finding that assured an
elevated incidence rate. 
Wartenberg et al. (1) justify inclusion of
the Henschler study as follows: “An argument
can be made that studies initiated by a cluster
report should be excluded … we disagree.”
This statement, with which we disagree, has
been and will continue to be debated in the
scientific literature (11,12). More immediate-
ly, the assignment of the Henschler study (9)
to Tier I status solely on the basis of the expo-
sure data specificity, without regard to its ori-
gin as a cluster investigation, represents a
methodologic weakness of the approach of
Wartenberg et al. This small cluster investiga-
tion overwhelmed the combined findings of
several large cohort studies. 
Looking at the data, it is obvious that the
positive result was produced by the Henschler
study (9). A more formal test, such as calcula-
tion of a Q statistic to assess homogeneity
across studies (2,13,14), demonstrates the
substantial heterogeneity between the
Henschler cluster evaluation and the three
large cohort studies (3–5).  The calculated Q-
statistic for the three large cohort studies, but
excluding the Henschler study, is associated
with a p-value of 0.47, whereas inclusion of
the Henschler study yields a p-value < 0.001,
which leads to formal rejection of the statisti-
cal hypothesis that the four studies are homo-
geneous. Although debate surrounds the value
of such testing as prerequisite to combing rel-
ative risks in meta-analyses, this case demon-
strates its utility.
In contrast, because Wartenberg et al. (1)
ignored the informative value of the exposure
data and instead emphasized methodologic
specificity, their approach might have
obscured an association between TCE and
renal cancer. An example of such concern is
the growing evidence that renal effects of
high- and low-dose TCE exposures are not
strictly dose related. It is probable that, under
some conditions, TCE is metabolized via glu-
tathione-dependent pathways to yield a
nephrotoxic metabolite, dichlorovinylcysteine
(DCVC) (15,16). There is also evidence
from animal studies that TCE does not cause
renal cancer in the absence of toxic tubular
injury (17). Moreover, studies of humans
with renal cancer indicate that those with a
history of high-dose TCE exposures also have
a significantly greater frequency and level of
proximal tubular damage than do those with-
out such an exposure history (18,19). 
Such findings suggest that if TCE
induces renal cancer in humans, it does so at
doses that also cause proximal tubular
nephritis. They also suggest that toxic
nephritis is necessary for TCE to cause renal
cancer (15,17). It can be reasonably antici-
pated that TCE-related nephritis occurs only
from exposures that exceed some threshold
dose and that lower-dose exposures would
not be expected to cause nephritis.
Accordingly, combining subjects with high
and not-so-high TCE exposures might con-
ceal whatever statistical association linked
TCE and cancer.
The subjects in the Henschler study (9)
were likely exposed to very high levels of TCE
for prolonged periods: “concentrations of 500
ppm were regularly achieved and exceeded in
this situation” (17). If so, subjects were
exposed to levels 10–20 times higher than
those reported for subjects in the other cohort
studies. Combining the subjects of those vari-
ous studies would serve to minimize any
underlying relationship between TCE and
renal cancer, particularly if most of the other
cohort subjects were exposed to levels below
the threshold dose expected to cause nephritis. 
Thus, for different but related reasons,
the Wartenberg approach could either
enhance a spurious association or obscure a
meaningful one. In this case, the former
seems to have occurred: inclusion of the
Henschler study (9) has probably led to a
spurious association. However, the more
important and general issue concerns appro-
priate methods for performing meta-analysis.
Meta-analyses that ignore important distin-
guishing features of individual studies, that
emphasize statistical procedures over biologic
and epidemiologic issues, and that disregard
homogeneity of exposure are unlikely to
resolve issues such as the human carcino-
genicity of TCE.
Jonathan Borak
Mark Russi
John Paul Puglisi
Yale University
New Haven, Connecticut
E-mail jborak@jborak.com
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TCE Meta-Analyses:
Wartenberg et al.’s Response 
We appreciate the interest of Borak, Russi,
and Puglisi in our summary of the epidemio-
logic evidence on the possible carcinogenicity
of trichloroethylene (TCE) (1). We share
their concern for a clear presentation of study
results and identifications of methods used in
meta-summaries of epidemiologic studies, and
labored to do so in our review. The ease with
which Borak et al. were able to identify cohort
studies that examined renal cancer incidence,
reproduce reported results, and recompute
estimates on a reduced set of study results
using the same summary methods belies their
criticism of concealment or obfuscation.
The principal goal in our review was to
identify, critique and summarize the cancer
epidemiology of TCE-exposed populations
in a more complete and systematic manner
than that carried out previously (2–4). As
such, our approach was to provide a broad
overview that summarized the major trends
and patterns in the data while reserving most
study-specific insights and patterns in the
data for other venues. Our challenge was to
examine and summarize the patterns of
results from over 80 epidemiologic publica-
tions that we identified. Although we recog-
nize the utility in certain contexts of select-
ing subjectively only the “best” studies and
reporting their results, as is done by IARC
(2), we explicitly chose not to do so. Rather,
we identified, critiqued, and summarized all
studies in a comprehensive assessment. Faced
with a large number of studies, we catego-
rized them by design and then subdivided
the cohort studies by the likelihood of TCE
exposure and the quality of the exposure
assessment. Some may quibble about our
particular categorization of the studies, but
we believe that our approach is well justified
overall and that the analyses were presented
clearly and comprehensively. Further, we do
not see this venue as the appropriate one to
debate the merits and limitations of meta-
analysis, in general, nor specifically the opin-
ions of Borak et al. regarding the interpreta-
tion of such analyses. This debate has
occurred elsewhere [e.g., see references in
Petitti (5)]. Our goal in calculating the aver-
age risks was to assess the possible role of
chance variation in the observed results and
to determine whether this body of studies
had sufficiently unusual results to warrant
further consideration and investigation. 
Borak et al. question the inclusion of the
controversial Henschler et al. study (6) in our
Tier I summary risk calculation. They suggest
that the study should have been excluded
because it originated as a cluster investigation.
They also note that the kidney cancer results
from the Tier I studies including the
Henschler et al. study (6) are statistically het-
erogeneous and thus misleading. 
The comment raised by Borak et al.
regarding the inclusion of the study by
Henschler et al. (6) has been raised by others,
notably Weiss (3) and McLaughlin and Blot
(4), and we explicitly addressed this issue in
the discussion of our paper. The notion that
data should be excluded from a general review
because they were first noted in a cluster seems
to misinterpret the very references (9,10) cited
by Borak et al. The context of those studies
was a discussion of the interpretation of a sin-
gle cluster study without exposure data and
without an a priori idea of what was being
investigated other than an overall excess of dis-
ease. First, the study by Henschler et al. (6) is
not a cluster investigation but a cohort study
that was initiated by the observation of excess
disease, albeit a cluster. Further, we included it
in a comprehensive review of the literature
because excess kidney cancer in this workplace
with extremely high TCE exposures was a
plausible a priori hypothesis based on both
animal bioassay and human epidemiologic
data that previously had shown increased renal
cancer rates from TCE exposure. Further, the
results of Henschler et al. (6) were so extreme
(5 cases where 0.628 were expected) that the
probability of observing such a situation is less
than 5 × 10–5, under Poisson assumptions. In
other words, if there were no association, one
would have to search for 500,000 similar
workplaces with comparable TCE exposures
to find such occurrence due to chance alone.
Therefore, these data warranted further con-
sideration, particularly with respect to other
studies of TCE exposure and renal cancer. We
agree that the study of Henschler et al. (6) is
not sufficient on its own to confirm a causative
relationship between TCE and renal cancer, as
Rothman (7) and Fleming et al. (8) caution
with respect to cluster studies. In combination
with all the other studies in our review, howev-
er, the case for an elevated kidney cancer risk is
much stronger.
Second, we are well aware of the issues sur-
rounding heterogeneity in meta-analyses
(9–13). We share Borak et al.’s concerns about
heterogeneity but disagree with their interpre-
tation. We did provide summary results for
each study for the interested reader who can
recalculate as they see fit, as Borak et al. did. If
we had provided only the average risks, we
would have obscured this issue and thus been
remiss. The general issue that we were con-
fronted with was how to help guide the reader
through 14 tables of data summarizing over 80
articles reporting cancer rates for 23 different
anatomical sites. Any summarization of this
volume of information will necessarily omit
some relevant information. Our point of sum-
marizing these data was to omit what we
thought was of lesser importance so that the
more casual reader would still understand the
main point of the paper without laboring over
all of the tables. In fact, we left out even more
data because most of the papers report on
either effects at several exposure levels or expo-
sures to several chemicals or responses to dif-
ferent subsets of the study population. When
available, we did present observations for the
most highly exposed subgroup to be consistent
with Henschler et al. (6). It was our judgment
that the information we included was the most
important information for the reader, given
the stated goal of our review. Those more
interested readers could recalculate various
summaries or even go back to the original
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investigation. We accept criticism on this issue
but note that we fulfilled our goal and provid-
ed a stimulus for scientific debate on the car-
cinogenicity of TCE. 
Despite their comments, Borak et al.
seem to place some weight on the elevated
kidney cancer risks reported by Henschler et
al. (6), because they explain that these
tumors may have resulted from high expo-
sure leading to tubular damage and subse-
quent cancer. We find this hypothesis
intriguing but not entirely satisfying since
some TCE metabolites, notably those of the
glutathione-S-transferase pathway, are highly
mutagenic (14,15). Therefore, tubular dam-
age may not be a necessary precursor to
TCE-induced renal cancer. Borak et al.’s
hypothesis, nonetheless, is worthy of replica-
tion in another highly exposed population. A
comparable study, however, may be difficult
to undertake because the average exposure
levels for populations in the remaining stud-
ies included in our analysis were substantially
lower than was typical in the Henschler et al.
study (6). For example, in the studies of
Axelson et al. (16) and Anttila et al. (17), the
median exposures were around 50 ppm,
lower than typically assumed in Henschler’s
cohort (7). Furthermore, incidence rather
than mortality should be evaluated due to
the differences in the rates between the two 
measures. In the end, Borak et al. apparently
agree with our interpretation that exposure
to TCE is a risk factor for renal cancer.
Unfortunately, we remain at odds with them
about our alternative approaches for summa-
rizing rather overwhelming amounts of
information.
In short, our analysis more strongly sug-
gests an association between TCE and renal
cancer. Renal cancer is a relatively rare disease
and our analysis is based on few incident
cases. The addition or subtraction of any one
study in the analysis can alter the magnitude
of the association. The findings of relative
risks above 1.0 for incidence in two of the
three other cohort studies (16–18) in Tier 1,
in addition to elevated risks between TCE
exposure and renal cancer in two recent
case–control studies (19,20), are supportive
of the overall association between elevated
renal cancer risk and TCE exposure.
Moreover, mode of action hypotheses regard-
ing the genotoxic effects of TCE metabolites
and their presence in the kidney add further
support for the human observations.
We recognize many limitations of our
approach to summarizing the large amount
of epidemiologic data on the possible car-
cinogenicity of TCE. Although other
approaches are possible and some have been
used in previous reviews of the epidemiologic
literature on TCE, they too have their short-
comings. We look forward to further discus-
sion and debate in the scientific community
leading to greater consensus about the possi-
ble hazards of TCE exposure.
Daniel Wartenberg
Daniel Reyner
Environmental and Occupational Health
Sciences Institute
UMDNJ-Robert Wood Johnson 
Medical School
Piscataway, New Jersey
E-mail: dew@eohsi.rutgers.edu
Cheryl Siegel Scott
U. S. Environmental Protection Agency
Washington, D.C.
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Particulate Matter Exposure
Assessment
Zeger et al. (1) did an excellent job of pre-
senting some of the possible effects of errors
in particulate matter (PM) exposure assess-
ment in time–series mortality analyses.
However, they (1) state,
our assessment of bias assumed that the health
effects of personal exposures to particles originating
indoors and outdoors are the same.
This assumption seems to ignore the vast
toxicology literature, such as the work of
Amdur et al. (2), which establishes that dif-
ferent particles do have different toxicity.
There are no traffic and industrial PM emis-
sions originating in a home. House dust and
cigarette smoke greatly affect indoor PM
concentrations, but barely affect ambient
PM measurements. Furthermore, ambient
PM may photochemically react with
hydroxide radicals, ozone, and nitrogen
dioxide and so may contain partially oxi-
dized and nitrated species not present in
indoor-generated PM. Inhalation of grams
per cubic meter of soil particles during the
1935 dust bowl days (3) and milligrams per
cubic meter of tars in tobacco smoke by
smokers may produce delayed and chronic
mortality effects from pneumonia and can-
cer, respectively, but no report in the litera-
ture states that such PM exposures produce
a next-day increase in mortality, which is
the basis for the PM time–series mortality
model of Zeger et al. (1). 
It has been shown (4), with the same
PTEAM data used by Zeger et al. (1), that I,
the exposure to indoor generated PM, I = (x –
α z), is uncorrelated with the magnitude of z,
where z is the outdoor PM concentration at
the subject’s home, x is the subject’s measured
total personal PM exposure, and α is the
time-weighted average fraction of the outdoor
PM to which the subject was exposed. That is,
the exposure to PM, from personal and
indoor sources of PM, was independent of z,
which is expected given the fact that z was
unknown; thus the people in the subjects’
homes could not consciously influence their
decisions to smoke, dust, or cook more or less
in relation to the changing value of z. This
supports Wilson and Suh (5), who argued
that the personal exposure measure desired is
α z, the total personal exposure to particles
from outdoor sources, not total personal
exposure. If the above analysis is valid, Zeger
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are more appropriately treated as separate pol-
lutants.” I therefore encourage the authors to
continue their fine work with that alternative
premise because their conclusion of a negative
bias, by treating indoor and ambient PM as a
single pollutant, may be incorrect.
David T. Mage
Institute for Survey Research
Temple University
Philadelphia, Pennsylvania
E-mail: davidm@temss2.isr.temple.edu
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Comments on “Determination
of Bisphenol A and Related
Aromatic Compounds Released
from Bis-GMA-Based
Composites and Sealants by
High Performance Liquid
Chromatography”
I was very much disappointed in the paper
by Pulgar et al. (1) because their laboratory
once again presented unreliable and confus-
ing HPLC data, regardless of my comments
(2) on their previous paper (3). They also
have provided no scientific response to my
criticism (2). 
The peak designated as BADGE in Figure
2A and C of their paper (1) is not bisphenol A
diglycidylether (BADGE) because its retention
time reads approximately 6 min from those
chromatograms, but it is given as 7.10 min in
their Table 1. This is supported further by
the gas chromatogram (GC) presented in
Figure 3A, which shows no peak for BADGE
at 27.9 min. Thus, it is reasonable to assume
that BADGE was not contained in Delton. 
In addition, the peaks designated as
bisphenol A propoxylate (PBPA) and bisphe-
nol A etoxylate (EBPA) in Figure 2C (1) are
doubtful because no peaks are noticeable at
27.7 and 23.9 min in the GC presented in
Figure 3A and no mass spectra are shown.
The presence of bisphenol A diglycidylether
methacrylate (Bis-GMA) in a polymerized
sample of Delton is not clear because Figure
3C shows no molecular ion peak for Bis-
GMA, whereas Pulgar et al. (1) identified a
GC peak at 22.8 min in Figure 3A as Bis-
GMA. 
Pulgar et al. (1) also present curious data
concerning the elution of bisphenol A (BPA)
and bisphenol A dimethacrylate (Bis-DMA)
in Tables 6, 8, and 10 and Tables 5, 6, and 9,
respectively. BPA eluted more in the poly-
merized samples than in the nonpolymerized
ones at all pHs indicated. This should be
reversed because the diffusion of BPA is usu-
ally more limited in polymerized samples
than in the nonpolymerized ones. The
increase in elution of Bis-DMA at pH 9 and
pH 12 compared to pH 1 and pH 7 is
unlikely because Bis-DMA is hydrolyzed
more easily at alkaline conditions than at
acidic or neutral conditions. 
Therefore, based on these reasons, I sug-
gest that the designation of each peak shown
in Figure 2 of Pulgar et al. (1) is not reliable,
and therefore all data shown in Tables 3–10
are also doubtful. I also suggest that the
HPLC analysis be performed more carefully
and thoroughly. Each peak should be carefully
examined to establish whether it originates
from a single pure compound or from a mix-
ture of different compounds. It is difficult to
separate the BPA peak from the those of other
compounds contained in Bis-GMA or Bis-
GMA-based resins under the HPLC condi-
tions used by Pulgar et al. (1). In their report
it appears that commercial Bis-GMA
monomer is a pure compound; however,
commercially available Bis-GMA is not pure
but a mixture of many compounds. 
My laboratory (4,5) has established that
commercial Bis-GMA is composed of many
minor components and four major compo-
nents: Bis-GMA, 2,2-[4-(2-hydroxy-3-
methacryloyloxy-1-propoxy)-4´-(3-hydroxy-
2-methacryloyloxy-1-propoxy)]diphenyl-
propane (Iso-bis-GMA), 2,2-[4-(2-hydroxy-3-
methacryloyloxy-1-propoxy)-4´-(2,3-dihy-
droxy-1-propoxy)] diphenylpropane (Bis-
GMA-H), and 2,2-[4-(2-hydroxy-3-
methacryloyloxy-1-propoxy)-4´-(2,3-
dimethacryloyloxy-1-propoxy)]diphenyl-
propane (Bis-GMA-M). We analyzed three
commercial Bis-GMA monomers and six Bis-
GMA-based composite resins including Z-
100, Charisma, and Tetric under the follow-
ing HPLC conditions: we used a C18 column
(flow of 1 mL/min) with acetonitrile/water
(50/50) as the solvent, a temperature of 40°C,
a duration of 55 min (isocratic mode), UV
detection (at 230 nm), and fluorescence (exci-
tation 275 nm; emission 300 nm) (5). Using
this HPLC analysis, we separated the peak of
BPA from that of Bis-GMA-H (which has a
peak at a retention time close to that of BPA)
and other impurities. Moreover, we also con-
firmed that BPA and Bis-GMA-H are includ-
ed in the same peak under certain HPLC
conditions (4). 
Quantification of the BPA content was
only possible when a fluorescence detector
was used, and it was impossible using a UV
detector because of the extremely low BPA
content (5). We found 43–130 µg BPA/g
Bis-GMA and 1.5–10.2 µg BPA/g unpoly-
merized composite resin. The contents of
Bis-GMA-H were measured at 18–50 mg/g
Bis-GMA and 1.1–1.4 mg/g composite resin
(5). The elution of Bis-GMA-H from poly-
merized Z-100 composite was 58 µg/g com-
posite in 37°C distilled water during a 24-hr
period (6). This value is within the range of
3–165 µg BPA/g polymerized composite at
pH 7 shown by Pulgar et al. (1) in their
Tables 4, 5, 7, 8, and 9. This suggests that
most of the “BPA” reported by Pulgar et al.
was probably Bis-GMA-H from the five Bis-
GMA-based resins. Regarding BPA content
in composite resins, Manabe et al. (7) report-
ed 6.4 µg BPA/g unpolymerized resin for a
commercial resin analyzed by GC-mass spec-
trometry. This value is quite similar to our
data. Thus, we sugggest that the BPA con-
tent in commercial dental resins is usually a
maximum of 10 µg/g resin. Moreover, long-
term leaching of BPA from a polymerized
resin in water has been predicted to be slight
and slow (6). Therefore, little or no long-
term estrogenic effect due to BPA contained
in Bis-GMA-based dental resins can be
expected. 
Finally, I suggest that Pulgar et al. (1)
replace the chemical structures for BADGE
and Bis-GMA shown in their Figure 1 with
correct ones. In conclusion, I suggest that
Pulgar et al. (1) withdraw the confusing data
presented in the paper or totally revise their
paper. 
Yohji Imai
Institute of Biomaterials and Bioengineering
Tokyo Medical and Dental University
Tokyo, Japan
E-mail: y-imai@i-mde.tmd.ac.jp
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Bisphenol A and Dental
Sealants: Olea’s Response
We have read the comments made by Imai
on our recently published paper (1) and once
again disagree with his interpretation of our
findings. Unfortunately, we are unable to
compare our results (1,2) with those cited by
Imai because four of the papers he cited were
published in the Dental Materials Journal,
which is not available in Europe. Because the
British Library was unable to furnish copies
of this journal, we assume that these articles
are not available to the international scientific
community. Perhaps these important papers
should be published in more accessible
journals.
Nevertheless, based on the account of the
methodologic approach described by Imai in
his letter, we believe that we used a superior
analytical method: a) we set the wavelength
of the UV detector at 280 nm, recommend-
ed for aromatic compounds (3); and b) we
used a gradient that provided a better resolu-
tion and a shorter time for running the chro-
matogram. The methods that we used to
detect bisphenols are now the international
gold standard (4–7).
We believe that Imai’s reading of our
paper is both simplistic and erroneous. He
produces interpretations of our figures which
go beyond the actual data that they contain.
Most of the concerns raised by Imai stem
from his overinterpretation of our Figure 2
(1). For example, his comments on the peaks
shown in our Figures 2C and 3 (1) imply that
all of the information presented in Tables
3–10 should be depicted in a single figure.
We chose to present one figure for each exper-
iment. The figures show chromatograms
selected from the set of tests that we per-
formed. It would be more fruitful to discuss
the results presented in the tables rather than
measuring the X-axes and speculating on the
basis of illustrations. 
Furthermore, we consider the use of
retention times for chemical identification, as
described in Imai’s letter, to be an inadequate
method because these times are relative to the
start of the chromatogram and follow a strict
sequence. GC/MS should always be the
method of choice for the interpretation of
these chromatograms. Imai’s charge of some
confusion between bisphenol A and Bis-
GMA-H can be easily refuted because the
analytical conditions that we used clearly dif-
ferentiated the two chemicals. Some of his
other comments are equally speculative and
lacking in scientific support. For instance,
Bis-GMA is usually broken in GC/MS and is
identified by its moieties.
In short, we cannot accept Imai’s inter-
pretation of our results. Above all, we regard
as highly speculative his claim for the none-
strogenicity of Bis-GMA-based dental resins
based on his group’s findings of little bisphe-
nol-A content. Unless he can demonstrate
the absence of estrogenicity in these samples,
his conclusions are tendentious and lacking
in scientific rigor.
Work in progress is revealing the 
presence of bisphenol A in the saliva of
Delton-treated patients several months after
exposure. These data, together with growing
evidence of estrogenic sealants and bisphenol
A in composite resins and saliva (8–12), are
increasing our concerns about the safety of
Bis-GMA-based resins.
Nicolas Olea
Laboratory of Medical Investigations
Department of Radiology
School of Medicine
HUSC-University of Granada
Granada, Spain
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Collision of Evidence and
Assumptions: TMI Déjà View
Evidence of health effects from radiation
released during the 1979 accident at the
Three Mile Island (TMI) nuclear generating
station continues to be of interest, especially
following the U.S. Supreme Court’s recent
reinstatement of claims of approximately
2,000 plaintiffs. Unfortunately, Talbott et
al.’s analysis of mortality of nearby residents
(1) does little to increase our understanding
of the accident’s health impact.
Talbott et al.’s paper (1) suffers from the
same logical mistake that we identified previ-
ously (2). Specifically, the authors undertook
a study in which empirical findings cannot
lead to rejection of the study’s null hypothe-
sis. Both Talbott et al. (1) and Hatch et al.
(3,4), who reported on the Columbia
University studies of cancer incidence, began
with the assumption that the maximum pos-
sible radiation doses from the accident were
well below average annual background radia-
tion levels. Even if standard radiation risk
estimates are underestimated by an order of
magnitude or more, such doses would be
associated with very small increases in cancer
in a general population with heterogeneous
susceptibility (2). Given the measurement
constraints of epidemiologic studies, it would
not be possible to detect an accident-related
increase in cancer at the dose levels assumed
by these authors. Thus, when they find
increased cancer rates among residents
assumed to have received relatively higher
radiation doses from the accident, such as the
significant linear trend in female breast can-
cer (1), the authors must conclude that the
association is not due to the exposure they are
studying. There is no scientific reason to con-
duct a study in which the null hypothesis
cannot be rejected due to a priori assump-
tions. This logical problem was further dis-
cussed in letters to EHP (5–8). Interestingly,
Talbott et al. (1) did not cite our paper,
which introduced this logical problem (2), or
the subsequent letters (5–8).
Talbott et al. (1) did not consider the
possibility that some people received radia-
tion doses from the TMI accident that were
substantially higher than background. Such
a possibility is supported by residents’
reports of acute symptoms following the
accident (9,10) and by evidence of elevated
chromosomal aberration rates among per-
sons reporting symptoms (11,12). The radi-
ation dose estimates used by Talbott et al.
depended on extensive assumptions about
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ments were available for individuals in the
study (13). Simplistic assumptions were
made about exponential decline of emissions
and dispersion over the first 10 days of the
accident (13). Further misclassification
should be expected from errors in responses
to survey questions about locations and
movements of persons during this time peri-
od. Inability to accurately classify doses in
an epidemiologic study threatens its ability
to detect effects. Neither Talbott et al. (1)
nor the authors of the Columbia studies
(3,4) discussed exposure measurement error
in interpreting their findings. 
Gur et al. (13), the authors of the
dosimetry report, state that their methodol-
ogy was developed “for educational, public
relations and defensive epidemiology pur-
poses.” This description of the rationale for
dosimetry reminds us of the constraints on
TMI dosimetry imposed upon other investi-
gators by court order (2,6). That order (14)
prohibited the investigators from making 
upper limit or worst case estimates of releases of
radioactivity or population doses… [unless] such
estimates would lead to a mathematical projection
of less than 0.01 health effects
and specified that 
a technical analyst… designated by counsel for the
Pools [nuclear industry insurers] concur on the
nature and scope of the [dosimetry] projects.
We were disappointed in the lack of detail
provided by Talbott et al. (1) regarding epi-
demiologic methods typically used in cohort
studies. An advantage of their study compared
to the Columbia University study (3,4) is that
exposed persons could be followed as they left
the area; however, there is no information
given regarding methods of vital status follow-
up, death certificate retrieval, or 
determination of loss to follow-up. Talbott et
al.’s (1) Table 1 presents information for a
“1992 cohort,” including the number of
households, implying that a second survey
of households might have been done.
However, no information is given to explain
the 1992 cohort or its relationship to the
1979 cohort.
Because exposed persons were followed,
Talbott et al. (1) could also have addressed
the problem of tracing birth cohorts through
time, a method that could not be employed
in the Columbia study (2). Fetal and child-
hood exposures appear to be particularly
effective in producing cancer (15,16); there-
fore, analyses of cancer mortality among per-
sons exposed at those ages would be of spe-
cial interest. Talbott et al. (1), however,
excluded persons younger than 18 years of
age from their dose–response analyses.
The number of persons and cancer deaths
included in relative risk regression analyses of
dose response were not given (1). These num-
bers may differ from those presented in Tables
1–4 not only because of the exclusion of per-
sons under 18 years of age but also because of
Talbott et al.’s requirement that members of
the cohort be born within 1 month of the case
in order to be included in the risk set for the
case. The authors gave no rationale for using
such a narrow restriction, which could limit
the size of risk sets, especially at older ages (the
median age for the cohort was reported as 29
years), leading to a possible loss of precision
because of small risk sets or even loss of cases
for which there were no eligible controls.
Studies of relationships between cancer
and environmental exposures typically take
into account latency periods known to occur
between exposure and disease. Failure to con-
sider exposure lag times reduces 
sensitivity to detect the effects under investi-
gation. Talbott et al. (1) presented no latency
analyses. 
Although the data collected by Talbott et
al. (1) appear to have the potential to advance
our understanding of mortality in the TMI
area, lack of information about the materials
and methods limits our ability to evaluate
their report. Furthermore, the statistical issues
raised above lead us to question the sensitivity
of their analysis to effects under investigation.
We hope that more information about this
study will be presented in the future, that fur-
ther analyses will be conducted using meth-
ods which increase the study’s sensitivity and
precision, and that interpretations will be
offered that are not inhibited by the a priori
assumption that positive results cannot be
interpreted as evidence in support of the
hypothesis being investigated. 
Steve Wing
Department of Epidemiology
School of Public Health
University of North Carolina
Chapel Hill, North Carolina
E-mail: steve_wing@unc.edu
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Lyon, France
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Re: “Collision of Evidence and
Assumptions: TMI Déjà View”
We appreciate the interest of Wing and
Richardson in our recent follow-up of 
mortality in the Three Mile Island (TMI)
cohort (1). We concur with the suggestion
that our data have the potential to advance
the overall understanding of the health
implications of the TMI incident. We also
welcome the opportunity to address several
of the issues raised and the concerns
expressed by Wing and Richardson within
the context of the strengths of our recent
mortality analysis.
The primary motivating factor for the
University of Pittsburgh in conducting the
TMI study (1) was to explore the unknown
nature of the health effects of low dose radia-
tion. No other study to date has followed
prospectively a large (n = 32,135), free-
living, non-occupationally exposed popula-
tion for an extended period. The only other
assessment of low-level exposure was in the
Hiroshima atomic bomb survivor studies
(2–4), which, by the overall nature of the
exposure, was relatively high compared to
the more recent TMI incident. 
In a reevaluation of an original study by
Hatch et al. (5,6) of cancer incidence in the
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specific factors may have detracted from the
ability of previous investigators to detect any
association of specific radiosensitive cancers
with low level radiation exposure at TMI,
including: a) the inaccuracy of estimates of
the magnitude of radiation exposure during
the TMI incident and b) poor classification
of relative exposures within the 10-mile study
area. The ecologic nature of the Columbia
University Study prevented access to individ-
ual cancer risk determinants (i.e., tobacco
smoking, education, etc.). Further, possible
misclassification associated with assignments
of exposure based on residence at the time of
diagnosis rather than at the time of the acci-
dent (5,6) may have occurred. We believe
that the methodology employed in our recent
mortality investigation addresses several of
these key issues. 
The individual dose estimates applied
to the TMI population in our study were
modeled by Gur et al. (8). Gur et al. used
the location of residence in relation to TMI
(both distance and direction) and informa-
tion on movements into and out of the
area during the 10 days after the accident
in conjunction with estimated time-depen-
dent dose–rate distributions to assign likely
and maximum possible doses to members
of the 13,000 households residing within a
5-mile radius of the TMI nuclear station.
The estimated time-dependent dose–rate
distribution used to assign individual dose
assessments was similar to that developed
by Woodard (9) and is described in detail
elsewhere (8). With the inclusion of migra-
tion factors, this individualized dose esti-
mate may represent a more sensitive 
measure of individual exposure than does
exposure assignment based on study tracts
constructed from census block boundaries
and meteorologic considerations. Hatch et al.
(5,6) noted the potential biases associated
with the study tract method, including an
inability to control for migration of the popu-
lation to and from the area and the potential
for exposure misclassification, particularly
with inward migration. The exposure mea-
sures generated by Gur et al. (8) and used in
our analyses should at the very least represent
a reasonable estimate of individual rather than
population-based exposure at the time of the
event, and reduce the likelihood of exposure
misclassification. 
We assessed sociodemographic data and
vital status through the TMI Population
Registry (10). This registry was a compilation
of individual descriptors collected at the time
of the special TMI Census in June l979.
Information collected included name,
address, age, sex, race, and a brief medical
history of cancer diagnoses, thyroid disorders,
radiation treatment or therapy, and prior
exposure to ionizing radiation on the job.
Pregnancies at the time of the accident were
noted and smoking history was recorded, as
well as the person’s daily travel in and out of
the 5-mile radius during the 10-day period.
The documentation of the tracing of vital sta-
tus of these individuals within this popula-
tion was extremely complete. To maintain
the follow-up registry, the Pennsylvania
Department of Health (PDoH), with the
cooperation of the U.S. Postal Service,
devised a system to annually obtain the cur-
rent addresses of persons in the registry with-
out contacting the registrant directly. Names
and addresses of all persons in the registry,
aged 16 years or older, are sent to the local
post office for address verification and
update. The post offices are obliged to
respond by supplying all relevant forwarding
address information on file. Many post
offices also correct spelling errors, indicate
deceased addressees, and supply other helpful
information. Each year, new current address-
es are added to the TMI Population Registry
database. Details of the follow-up from l979
through l992 are presented in Table 1. The
PDoH follow-up yielded only 121 individu-
als who did not have a verified address and
vital status through 1992. This represents
0.5% lost to follow-up, or a 99.5% success
rate in tracing individuals in this cohort (11). 
After the l979 incident, the PDoH has
updated mortality status annually. The TMI
Population Registry data set is matched year-
ly against the death certificate file maintained
by the department’s Health Data Center to
identify those TMI residents that have died
in Pennsylvania. For TMI residents who have
relocated outside of Pennsylvania, the PDoH
has an agreement with the National Center
for Health Statistics (NCHS) to match the
TMI population registry file once every 3
years with the National Death Index (NDI)
file maintained by NCHS to identify those
who have died outside of Pennsylvania. Data
on potential confounders (i.e., sex, race,
smoking status, and education) collected at
baseline and information on the outcome of
interest in the exposed population (i.e., mor-
tality) through 1992 was available for our
mortality assessment. Through access of the
current NDI national death certificate pro-
gram, it will be possible to trace all individu-
als though 1998 and beyond with the same
amount of success.
As we suggested in the “Discussion” of
our paper (1), mortality, as a function of both
incidence and case fatality, may be different
from incidence patterns in the TMI cohort.
Therefore, it will be important to monitor
both cancer incidence and mortality with
respect to individualized dose estimates in
this population to determine if incidence
mirrors the observed mortality experience.
However, the mean latency of most radiosen-
sitive solid tumor cancers (lung, breast, and
lymphopoetic–hematologic tissue) is 20–30
years (12), and this population is only now
experiencing these tumors. In the 1998 fol-
low-up currently in-progress, we intend to
assess the significance of this long-term laten-
cy and its relationship to cancer incidence
and mortality in the TMI population. 
Wing and Richardson suggest that the
exposures to the population on the day of the
accident may have been far greater than pre-
viously estimated. In fact, they reference
apparent chromosomal effects in this popula-
tion as potentially attributable to low-level
radiation (13,14). A total of 29 blood sam-
ples were collected from predominantly older
individuals near TMI 15 years after the acci-
dent (13,14). There was no local control
group and no adjustment for confounding
(smoking, occupational exposure) or other
environmental insults during this 15-year
elapsed period. Hence we can not rule out a
spurious cause and effect. 
Because we are aware that exposure mis-
classification error remains a possibility, we
agree that it may be reasonable to consider a
worst-case scenario regarding exposure, if in
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Table 1. Distribution of TMI cohort by year of follow-up, 1979–1992.
Lost to  Death  No death 
Year Populationa follow-up Deaths certificate certificate
1979 32,135 0 166 166 0
1980 31,969 4 336 336 0
1981 31,633 20 322 322 0
1982 31,311 6 310 310 0
1983 31,001 6 312 310 2
1984 30,689 0 301 300 1
1985 30,388 2 303 303 0
1986 30,085 11 263 261 2
1987 29,822 0 278 277 1
1988 29,544 8 263 260 3
1989 29,281 0 274 273 1
1990 29,007 25 288 284 4
1991 28,719 0 263 261 2
1992 28,456 39 266 262 4
aLost to follow-up included in population value.fact increases in cancer mortality or morbidity
are observed in this population over time.
With the data analysis thus far, we have noted
no increases that would allude to a more seri-
ous exposure scenario than we previously sug-
gested. Assuming, however, that exposure was
underestimated across all levels of either likely
or maximum gamma, we suggest that a linear
trend, if not an absolute association, should be
evident if all cause or cause-specific mortality
was associated with increasing exposure to
low-level radiation.
Our finding of a significant trend of
higher likely gamma with increasing breast
cancer risk is therefore important. We cited
two statistical probabilities in the assessment
of this association. The global p-value reflect-
ed the statistical significance in assessing
overall breast cancer risk when comparing
risk levels to the lowest category of each risk
factor as baseline. This global p-value was
not significant (p = 0.17), indicating no
overall difference in breast cancer when the
reference group for low gamma exposure was
compared to all remaining groups. However,
the test for linear trend, which assessed
whether a statistically significant dose
response was evident when comparing
groups to the baseline risk category, was in
fact statistically significant (p = 0.02). The
risk estimates by exposed and nonexposed
subjects suggest possible dose response in
incrementally dosed groups (1.76, 1.76, and
2.42). However, multiple comparison
adjustments were not considered in this
study. Multiple comparison problems occur
and often yield significance because of the
sheer number of tests done on a population.
We have continued to follow the trend in
breast cancer and likely gamma exposure in
the 1995 update. The data indicate that the
trend is slightly attenuated and no longer sta-
tistically significant. Continued follow-up of
this population is critical to reconciling this
important issue.
We agree with Wing and Richardson’s
comment that using a matching criterion of a
1-month caliper in date of birth may be too
precise for such an epidemiologic study.
However, we were constricted by hardware
and software limitations at the time of the
analyses. Because of the size of the total
cohort, the risk sets were extremely large,
resulting in computational difficulties. The 1-
month caliper was used to decrease the risk set
size to a more manageable level. This tight
match resulted in a loss of only four deaths in
the analysis. In comparison to the total
deaths, we felt that this was loss was minimal.
Fortunately, these software and hardware lim-
itations are no longer an issue, and such a
tight match will not be necessary in future
updates.
Because childhood cancers are quite dif-
ferent in both presentation and pathology
than those manifesting in adults, the mortali-
ty and incidence experience of the children of
TMI (< 18 years of age) is currently being
assessed in a separate analysis that includes
mortality data through 1998. Because poten-
tial confounders (education and smoking)
were not available for those < 18 years of age
at the time of the accident, we restricted our
relative risk regression analysis to those ≥ 18
years of age. Table 2 shows the number of
observed deaths for each outcome of interest
used in relative risk regression modeling. Also
shown is the total number of deaths for the
same cause categories that were used in the
standardized mortality ratio analyses. As seen
in Table 2, 0–4 deaths were omitted when
subjects were restricted to those ≥ 18 years of
age. Through 1992, a total of six deaths from
neoplasms had occurred in individuals < 18
years of age at the time of the accident. 
It is reassuring to note that Eastman Kodak
(Rochester, NY), in an independent effort, col-
lected and analyzed high-speed photographic
film located in the area during the TMI releases
(15). None of the film showed any unusual
fogging. The minimum exposure level at which
fogging occurs is 5 mrem, and no film received
an exposure in excess of that amount. At this
time, the impact of the radiation exposure from
the TMI incident on the mortality of the resi-
dents appears minimal. However, due to laten-
cy in the development of several radiosensitive
malignant neoplasms, we plan to continue our
active involvement in the monitoring of health
risks in the TMI cohort. 
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Table 2. Number of observed deaths available for relative risk regression modeling.
Males Females
≥ 18 years <18 years Total ≥ 18 years <18 years Total
All heart causes 814 3 817 851 2 853
All malignancies 419 4 423 382 2 384
Bronchus, trachea,  147 0 147 56 0 56
and lung cancer
All lymphopoietic and  40 3 43 47 0 47
hematopoietic cancer
CNS cancer 6 0 6 11 1 12
Breast cancer NA NA NA 78 0 78
Abbreviations: CNS, central nervous system; NA, not available.
Correction
In the September 2000 issue of EHP, a
photograph of both chestnuts and hazel-
nuts was printed as accompaniment to an
article discussing only hazelnuts [“Going
Nuts over Paclitaxel,” EHP 108:A397
(2000)]. EHP apologizes for any resulting
confusion.